Table 4.
Cox-regression multivariate analysis of PFS and OS
| Factors | PFS (months) | OS (months) | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| CEA level (≤ 15 / > 15 ng/ml) | 1.906(1.107–3.283) | 0.020 | 2.493(1.146–5.423) | 0.021 |
| Pathological classification (Low/Middle-High differentiated) | 1.298(0.707–2.384) | 0.400 | 1.972(0.793–4.906) | 0.144 |
| TNM stage (stage I-III/IV) | 2.749(1.412–5.351) | 0.003 | 9.215(3.199–26.549) | 0.000 |
| Number of LO (≤ 2 / > 2 LO) | 2.150(1.100–4.200) | 0.025 | 1.678(0.772–3.650) | 0.192 |
| Cumulative GTV (≤ 40 / > 40 cm3) | 2.012(1.060–3.821) | 0.033 | 4.164(1.791–9.679) | 0.001 |
| System treatments(C + TT/C alone) | - | - | 2.388(1.024–5.572) | 0.044 |
CI Confidence interval, HR hazard ratio, OS overall survival, PFS progression-free survival, LO Lung oligometastases, C Chemotherapy, TT target therapy